A review was recently published in the Journal of Neurochemistry which acknowledged PD-MitoQUANT research funding. "α‐synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities" authored by a team consisting of Parvez Alam, Luc Bousset, Ronald Melki and Daniel E. Otzen appeared in the 29 June 2019 issue. Ronald and Luc are PD-MitoQUANT PIs from the Centre National de la Recherche Scientifique, the CNRS in France. Congratulations to all! DOI: 10.1111/jnc.14808 Download the open access paper here.
A few questions were posed to PI Prof Dr Donato (Dino) DiMonte to gain his views on his work in Parkinson research and PD-MitoQUANT, in general. Dino is a senior researcher and leads the Neurodegeneration and Neuroprotection in Parkinson’s Disease Group at the German Center for Neurodegenerative Diseases (DZNE). Please describe your day to day work. It is difficult to describe a “typical” day of work. Most of the time, our working schedule involves specific tasks that vary from day [...]
The 5th World Parkinson Congress (WPC) was held in Kyoto, Japan from June 4– 7, 2019. More than 3,000 people from more than 60 countries attended the meeting. At this meeting, Dr Ronald Melki of the Centre National de la Recherche Scientifique (CNRS) and PD-MitoQUANT PI presented: "What is alpha-synuclein- The biology". Through Ronald's talk, PD-MitoQUANT funding was acknowledged. Dr Ronald Melki, CNRS at WPC 2019 The WPC 2019 hosted an international, interdisciplinary forum showcasing the most important [...]
Beckie Port "From innovation to better treatments" is the title of a blog post published on 27 May 2019 by Dr Beckie Port. Beckie is Research Communications Manager at PD-MitoQUANT partner Parkinson's UK. This blog entry announces partnerships with two pan-European, IMI-funded research projects: PD-MitoQUANT and Neuronet. In it, Beckie describes how these collaborative projects aim to accelerate research and deliver new treatments for Parkinson’s. Read the full blog post here.
PD-MitoQUANT PI Ronald Melki of the Centre National de la Recherche Scientifique (CNRS) recently delivered the plenary lecture of the Frontiers in Neuroscience session of the American Academy of Neurology (AAN) annual meeting on May 8, 2019, in Philadelphia, USA. Through his talk, PD-MitoQUANT funding was acknowledged. More than 3000 were in attendance. The theme of the 71st AAN annual meeting was "Advancing Neurology, Advancing You". It was held May 4- 10th. The meeting offers unparalleled opportunities for professional and personal advancement [...]
PD-MitoQUANT recently appeared in the news stream of HealthEuropa.eu. Read the story, “The Innovative Medicines Initiative, mitochondrial dysfunction and Parkinson’s". Read the story here. Health Europa highlights the latest trends and developments in health and healthcare from across Europe. Their platform is a valuable news source to the health sector, allowing them to discuss research and innovation themes, health policy and new technologies. In addition, the website, HealthEuropa.eu has gained Google News approval. It features news, interviews and insightful commentary from leading figures, keeping readers [...]
Here is a list of international and national media coverage of the launch of PD-MitoQUANT: Bioengineer.org: Ireland to lead €7 million Parkinson's research project. Read the story here. SCIENMAG: Ireland to lead €7 million Parkinson's research project. Read the story here. Hospital Pharmacy Europe: Ireland to lead on €7 million Parkinson's research project. Read the story here. Bio Spectrum Asia: Ireland to lead €7 M Parkinson's research project. Read the story here. SiliconRepublic.com: Ireland’s RCSI to lead €7m Parkinson’s research project. Read the story here. Irish Mirror: €7m [...]
7 million euro awarded for Parkinson’s research through Innovative Medicines Initiative New, more effective treatments are urgently needed for the more than one million people living with Parkinson’s in Europe today. While there are therapies available for the condition, they do not improve all symptoms, nor do they slow or prevent disease progression over time, and long-term treatment is associated with adverse side effects. PD-MitoQUANT (www.pdmitoquant.eu) is an Innovative Medicines Initiative (IMI - www.imi.europa.eu) research project that will improve [...]
The PD-MitoQUANT team had a very successful kick-off meeting last week in RCSI! We reviewed our work plan and discussed the planned activities for the first year of the project. We're going to be busy! To learn more about the project, check out our Project page. If you're on twitter, join our conversation #pdmitoquant! 08/03/2019, PD MitoQUANT Kick Off Meeting at RCSI, 123 St. Stephen's Green, Dublin 2. (Picture: Lafayette Photography)